← Leaderboards
Madhavan P Nair
State University Of New York At Buffalo
$24,745,414
Attributed
$27,277,711
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$27,277,711 · 14
By mechanism
R01$25,176,309 · 11
R37$1,670,402 · 1
R21$387,500 · 1
R13$43,500 · 1
Top collaborators
- Kamel Khalili5 shared
- Alexandros Makriyannis5 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Marilyn Emily Morris$3,163,244
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1Hiv InfectionsIn VitroCellsInfectionPreventNeuronsBrainVirusIn VivoPharmaceutical PreparationsMediatingMonocytePropertyLiposomesProteinsBiological ModelsLeadDrug Delivery SystemsMouse ModelNanoparticleDrug Of AbuseBlood - Brain Barrier AnatomyResponse
Grant awards (77)
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,610
R01 · FY2023 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,861
R01 · FY2022 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$371,100
R01 · FY2021 · DA · contact PI
Effect of a potent and metabolically stable endocannabinoid receptor agonist on inflammasome-induced neuroinflammation in a comorbid mouse model of Alzheimer's disease and HIV$364,202
R01 · FY2021 · DA · contact PI
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers$608,297
R01 · FY2020 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$383,202
R01 · FY2020 · DA · contact PI
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers$621,856
R01 · FY2019 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$527,958
R01 · FY2019 · DA · contact PI
To evaluate the role of cannabinoid signaling during the comorbidity of HIV and Alzheimer¿s disease in the context of HIV-associated cognitive disorders$364,031
R01 · FY2019 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$6,523
R01 · FY2019 · DA · contact PI
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers$638,630
R01 · FY2018 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$530,025
R01 · FY2018 · DA · contact PI
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2$365,824
R01 · FY2018 · DA · contact PI
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells and$362,500
R01 · FY2018 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$12,788
R01 · FY2018 · DA · contact PI
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers$654,996
R01 · FY2017 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$530,713
R01 · FY2017 · DA · contact PI
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells and$362,500
R01 · FY2017 · DA · contact PI
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers$680,840
R01 · FY2016 · DA · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$529,498
R01 · FY2016 · DA · contact PI
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2$364,122
R01 · FY2016 · DA · contact PI
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells and$358,875
R01 · FY2016 · DA · contact PI
3rd Annual Personalized NanoMedicine Symposium$43,500
R13 · FY2016 · MD · contact PI
Nano-delivery of methanandamide across BBB to block cannabinoid induced effects in HIV-1 infection$520,084
R01 · FY2015 · DA · contact PI
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2$360,337
R01 · FY2015 · DA · contact PI
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells and$357,062
R01 · FY2015 · DA · contact PI
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2$363,559
R01 · FY2014 · DA · contact PI
Multifunctional Nanocarrier to Eradicate HIV from latently infected CNS cells and$362,500
R01 · FY2014 · DA · contact PI
Mechanisms of Neuro-AIDS by HIV 1B and C Clades$331,860
R01 · FY2014 · MH · contact PI
Novel Magneto-Electric Nanodelivery of Drugs to Eradicate HIV from CNS$206,250
R21 · FY2014 · MH · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$4,320
R01 · FY2014 · DA · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$677,521
R01 · FY2013 · DA · contact PI
Cocaine in the Neuropathogenesis of HIV infection: Role of HDAC2$363,559
R01 · FY2013 · DA · contact PI
Mechanisms of Neuro-AIDS by HIV 1B and C Clades$318,586
R01 · FY2013 · MH · contact PI
Novel Magneto-Electric Nanodelivery of Drugs to Eradicate HIV from CNS$181,250
R21 · FY2013 · MH · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$622,829
R01 · FY2012 · DA · contact PI
Mechanisms of Neuro-AIDS by HIV 1B and C Clades$331,860
R01 · FY2012 · MH · contact PI
Role of Cocaine in Neuro-AIDS by HIV 1B and C Clades$325,949
R37 · FY2012 · DA · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$89,900
R01 · FY2012 · DA · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$641,993
R01 · FY2011 · DA · contact PI
Mechanisms of Neuro-AIDS by HIV 1B and C Clades$331,860
R01 · FY2011 · MH · contact PI
Role of Cocaine in Neuro-AIDS by HIV 1B and C Clades$325,949
R37 · FY2011 · DA · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$554,518
R01 · FY2010 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$401,725
R01 · FY2010 · DA · contact PI
Mechanisms of Neuro-AIDS by HIV 1B and C Clades$346,462
R01 · FY2010 · MH · contact PI
Role of Cocaine in Neuro-AIDS by HIV 1B and C Clades$336,029
R37 · FY2010 · DA · contact PI
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease$549,593
R01 · FY2009 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$404,110
R01 · FY2009 · DA · contact PI
Role of Cocaine in Neuro-AIDS by HIV 1B and C Clades$337,768
R37 · FY2009 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$403,015
R01 · FY2008 · DA · contact PI
Role of Cocaine in Neuro-AIDS by HIV 1B and C Clades$344,707
R37 · FY2008 · DA · contact PI
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$333,053
R01 · FY2008 · DA · contact PI
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$339,850
R01 · FY2007 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$333,514
R01 · FY2007 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$77,203
R01 · FY2007 · DA · contact PI
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$449,687
R01 · FY2006 · DA · contact PI
Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine$357,276
R01 · FY2006 · DA · contact PI
AIDS encephalopathy and HIV disease: role of opioids$336,016
R01 · FY2006 · DA · contact PI
AIDS encephalopathy and HIV disease: role of opioids$47,260
R01 · FY2006 · DA · contact PI
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$10,977
R01 · FY2006 · DA · contact PI
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$392,500
R01 · FY2005 · DA
AIDS encephalopathy and HIV disease: role of opioids$392,500
R01 · FY2005 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$292,318
R01 · FY2005 · DA
Cocaine in the Immuno and Neuropathogenesis of HIV-1 Infection$79,250
R01 · FY2005 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$60,932
R01 · FY2005 · DA
AIDS encephalopathy and HIV disease: role of opioids$392,500
R01 · FY2004 · DA
Cocaine/Immuno and Neuropathogenesis of HIV-1 Infection$392,500
R01 · FY2004 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$353,250
R01 · FY2004 · DA
AIDS encephalopathy and HIV disease: role of opioids$392,500
R01 · FY2003 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$352,688
R01 · FY2003 · DA
COCAINE &IMMUNO AND NEUROPATHOGENESIS OF HIV1 INFECTION$257,194
R01 · FY2003 · DA
AIDS encephalopathy and HIV disease: role of opioids$390,000
R01 · FY2002 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$350,438
R01 · FY2002 · DA
COCAINE &IMMUNO AND NEUROPATHOGENESIS OF HIV1 INFECTION$249,706
R01 · FY2002 · DA
HEROIN AIDS ENCEPHALOPATHY--NEUROPATHOGENESIS MECHANISMS$348,188
R01 · FY2001 · DA
COCAINE &IMMUNO AND NEUROPATHOGENESIS OF HIV1 INFECTION$242,434
R01 · FY2001 · DA
COCAINE &IMMUNO AND NEUROPATHOGENESIS OF HIV1 INFECTION$235,371
R01 · FY2000 · DA